Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine)

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Chemotherapy; Decitabine; Epigenetics; Non small cell lung cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DNA METHYLATION; DRUG DOSE INCREASE; DRUG MECHANISM; EPIGENETICS; GENE SILENCING; GRANULOCYTOPENIA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PILOT STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84891073380     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00188     Document Type: Article

References (26)

1. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 20:4285-4291.
2. Scagliotti GV, Parikh P, von PawelJ, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 26:3543-51.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 346:92-8.
4. Momparler RL. Pharmacology of 5-aza-2'-deoxycytidine (decitabine). Semin Hematol (2005) 42S9-16.
5. Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (Decitabine). Semin Oncol (2005) 32:443-51.
6. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs (1997) 8:358-68.
7. Momparler RL, Ayoub J. Potential of 5-aza-2'-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for the therapy of advanced non-small cell lung cancer. Lung Cancer (2001) 334S111-5.
8. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 12:5777-85.
9. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, et al. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer (2008) 8::128.
10. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer (2006) 6:583-92.
11. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia. Cancer (2006) 107:116-24.
12. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics (2013) 5::3.
13. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 1:598-607.
14. Boivin A-J, Momparler LF, Hurtubise A, Momparler RL. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anti-Cancer Drugs (2002) 13:869-74.
15. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer (2005) 4:1223-36.
16. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 17:645-54.
17. Ito M, Ito G, Kondo M, Uchiyama M, Fukui T, Mori S, et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett (2005) 225:131-9.
18. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 64(14):4717-20.
19. Richards KL, Zhang B, Sun M, Dong W, Churchill J, Bachinski LL, et al. Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer (2011) 117:606-17.
20. Suzuki M, Shigematsu H, Takahashi T, Shivapurkar N, Sathyanarayana UG, Iizasa T, et al. Aberrant methylation of Reprimo in lung cancer. Lung Cancer (2005) 47:309-14.
21. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res (2007) 13:6087-92.
22. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A (2007) 104: 5527-32.
23. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis (2009) 30:1132-8.
24. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, Belinsky SA. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene (2010) 29:5159-5170.
25. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer (2007) 58:131-8.
26. Zhang YW, Miao YF, Yi J, Geng J, Wang R, Chen LB. Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma (2010) 57:228-33.